TrinityPoint Wealth LLC Invests $40,000 in Coherus BioSciences, Inc. (NASDAQ:CHRS)

TrinityPoint Wealth LLC bought a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRSFree Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,038 shares of the biotechnology company’s stock, valued at approximately $40,000.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its position in Coherus BioSciences by 10.5% in the third quarter. Vanguard Group Inc. now owns 9,782,127 shares of the biotechnology company’s stock valued at $36,585,000 after acquiring an additional 932,476 shares in the last quarter. Barclays PLC increased its stake in Coherus BioSciences by 3,105.3% during the 3rd quarter. Barclays PLC now owns 2,375,557 shares of the biotechnology company’s stock worth $8,884,000 after buying an additional 2,301,444 shares during the period. Rafferty Asset Management LLC acquired a new position in Coherus BioSciences in the 3rd quarter worth $3,277,000. Brandywine Global Investment Management LLC boosted its position in Coherus BioSciences by 64.7% in the 3rd quarter. Brandywine Global Investment Management LLC now owns 666,245 shares of the biotechnology company’s stock valued at $2,492,000 after buying an additional 261,800 shares during the last quarter. Finally, CM Management LLC grew its stake in shares of Coherus BioSciences by 21.8% during the third quarter. CM Management LLC now owns 548,000 shares of the biotechnology company’s stock valued at $2,050,000 after acquiring an additional 98,000 shares in the last quarter. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on CHRS shares. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Coherus BioSciences in a report on Friday, May 24th. Truist Financial reduced their target price on Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.83.

View Our Latest Stock Report on CHRS

Coherus BioSciences Trading Down 1.6 %

Shares of NASDAQ CHRS opened at $1.88 on Wednesday. The company has a market capitalization of $215.69 million, a price-to-earnings ratio of -2.41 and a beta of 0.56. Coherus BioSciences, Inc. has a twelve month low of $1.43 and a twelve month high of $5.63. The business has a 50 day simple moving average of $2.20 and a 200-day simple moving average of $2.31.

Coherus BioSciences (NASDAQ:CHRSGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.33). The business had revenue of $77.06 million for the quarter, compared to analysts’ expectations of $102.00 million. During the same period in the previous year, the company posted ($0.89) earnings per share. As a group, equities analysts predict that Coherus BioSciences, Inc. will post -1.14 earnings per share for the current year.

About Coherus BioSciences

(Free Report)

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.

Featured Stories

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with's FREE daily email newsletter.